Apr 15, 2020 - Health

Gilead has filed for a trademark on the bottle for a coronavirus drug

What Gilead wants its remdesivir bottle to look like. Photo: U.S. Patent and Trademark Office

Gilead Sciences is still testing its potential coronavirus treatment, but here's a sign the company may be expecting good news: It has applied for a trademark for the drug's packaging.

Why it matters: "The reason you make this trademark is because you think you're going to get a product out there soon," said Josh Gerben, a trademark lawyer who first noticed Gilead's application. "This is part of your brand protection."

The big picture: Gilead's drug, remdesivir, is seen as a promising candidate to treat the novel coronavirus, but is still undergoing clinical trials and hasn't been proven to work.

  • Gilead is slated to release new data on remdesivir data later this month, from randomized trials in China.
  • Filing for a packaging trademark indicates the company is seriously thinking about this drug's branding and mass distribution.

What they're saying: A Gilead spokesperson says the trademark application "is par for the course" and "entirely consistent with our stated responsibility to plan for a potential regulatory authorization should remdesivir be proven safe and effective."

Gilead has already trademarked the same blue-and-gray bottle top and white labeling in other federally approved drugs.

Go deeper

16 hours ago - Health

Hydroxychloroquine failed to prevent coronavirus infections

Photo: George Frey/AFP via Getty Images

Hydroxychloroquine, a drug that treats malaria and lupus, did not prevent people from getting COVID-19 if they were exposed to the virus, according to data from a randomized, placebo-controlled clinical trial published in the New England Journal of Medicine.

The bottom line: There has been widespread confusion about hydroxychloroquine's effectiveness — President Trump and other conservatives touted the pill with little sound evidence, while other flawed studies suggested it was harmful. But this trial authoritatively says the drug "didn't work" as a preventive medication for this coronavirus, a Vanderbilt University infectious disease doctor told the Washington Post.

17 hours ago - Health

World Health Organization resumes hydroxychloroquine trial

WHO director-general Tedros Adhanom Ghebreyesus. Photo: Fabrice Coffrini/AFP via Getty Images

The World Health Organization will resume its hydroxychloroquine trial after its safety committee found "there are no reasons to modify the trial protocol," WHO's director-general Tedros Adhanom Ghebreyesus said at a press briefing Wednesday.

The big picture: The organization temporarily suspended its trial for the antimalarial drug last week after an analysis published in The Lancet showed coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm.

The risk asset rally continues as stock market rebounds

Illustration: Sarah Grillo/Axios

Risk assets have jumped over the past week and continued their rally on Wednesday, with the S&P 500 gaining for a fourth straight day and posting its highest close since March 4, while the Nasdaq ended the day just 1.4% below its all-time high.

What it means: If it hadn't been evident before, Wednesday's market action made clear that the bulls are back in charge.